Core Insights - Best Buy Co., Inc. (BBY) reported fourth-quarter fiscal 2026 results with revenues below expectations and earnings exceeding estimates, showing a year-over-year decline in revenue but an increase in earnings [1][6]. Financial Performance - Adjusted earnings per share were $2.61, surpassing the Zacks Consensus Estimate of $2.48, and increased by 1.2% from $2.58 in the previous year [6]. - Total enterprise revenues were $13,814 million, falling short of the consensus estimate of $13,907 million, and declined by 1% from $13,948 million in the prior year [7]. - Gross profit decreased by 1.2% to $2.88 billion, with a gross margin remaining flat at 20.9% year over year [7][11]. - Adjusted SG&A expenses were $2.19 billion, down 1.8% year over year, with SG&A as a percentage of revenues decreasing by 20 basis points to 15.8% [8]. Operational Highlights - Best Buy adapted to a dynamic holiday environment with uneven consumer demand, adjusting marketing and labor deployment in real time [2]. - Key focus areas included computing and mobile phones, with growth in emerging technology segments like AI-enabled devices and gaming accessories, although big-ticket items like home theater and appliances saw continued softness [3]. - The company emphasized efficiency improvements across fulfillment, customer care, and supply-chain functions, leveraging technology for enhanced personalization and delivery speed [4]. Customer Experience and Market Response - Customer experience improvements were noted across satisfaction metrics, leading to a 7.1% increase in BBY shares following the quarterly update [5]. - Domestic revenues totaled $12.58 billion, reflecting a 1.1% year-over-year decline, while international revenues were $1.24 billion, meeting estimates and increasing by 0.5% year over year [9][12]. Future Outlook - For fiscal 2027, Best Buy expects revenues between $41.2 billion and $42.1 billion, with comparable sales projected to fluctuate between a 1% decline and 1% growth [16]. - The company anticipates a gross margin improvement of 30 basis points, driven by growth in advertising and the U.S. Marketplace platform [16]. - Adjusted operating margin is expected to be between 4.3% and 4.4%, with adjusted earnings per share forecasted at $6.30 to $6.60 [19].

Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 3.8% excluding COVID testing sales, with adjusted earnings per share (EPS) of $1.50 reflecting a growth of 12% compared to the prior year [18] - Adjusted gross margin was 57.1% of sales, an increase of 20 basis points year-over-year, while adjusted operating margin rose to 25.8%, reflecting an increase of 150 basis points [18] - The company forecasts adjusted EPS for 2026 to be in the range of $5.55-$5.80, indicating a 10% growth at the midpoint [19] Business Line Data and Key Metrics Changes - Nutrition sales declined in Q4, impacted by market share loss and increased manufacturing costs, with a focus on reigniting volume growth through price and promotion initiatives [9][10] - Diagnostics sales decreased by 3.5% due to a decline in COVID testing, while Core Lab Diagnostics grew by 3.5%, achieving accelerating growth [11] - EPD (Established Pharmaceuticals Division) saw a 7% increase in sales, with double-digit growth in India and several Latin American and Middle Eastern countries [12] - Medical devices sales grew by 10.5%, driven by a 12% increase in continuous glucose monitors and strong performance in electrophysiology and structural heart segments [12][14] Market Data and Key Metrics Changes - The U.S. pediatric nutrition business faced challenges due to market share loss and increased price sensitivity among consumers [9][10] - Core Lab Diagnostics growth was 7% excluding China, reflecting durable demand globally [11] - EPD's growth was well-balanced across markets, with significant contributions from emerging markets [12] Company Strategy and Development Direction - The company aims to transition back to a more balanced growth profile, focusing on volume growth alongside price increases [10] - The acquisition of Exact Sciences is expected to enhance Abbott's position in the cancer diagnostics market, adding a high-growth business to its portfolio [8] - The company plans to launch at least eight new products in the nutrition segment over the next 12 months to support growth [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the nutrition business but expressed confidence in the ability to reignite volume growth and return to positive growth in the second half of 2026 [27] - The company expects continued momentum in most business segments, with a focus on innovation and operational excellence driving growth [8][29] - Management highlighted the importance of addressing price sensitivity and the need for a sustainable growth strategy in the nutrition segment [25][27] Other Important Information - The company anticipates a favorable impact from foreign exchange on full-year reported sales, estimated at around 1% [19] - The adjusted tax rate is forecasted to be in the range of 15%-16% for the year [19] Q&A Session Summary Question: Concerns about revenue growth guidance - Management acknowledged a slight reduction in top-line guidance primarily due to challenges in the nutrition business but maintained EPS guidance in line with consensus [23][24] Question: Insights on the EP product portfolio - Management emphasized the successful launch of the Vault PFA catheter and the strategic positioning of Abbott's EP portfolio, expecting to grow in line with market trends [34][39] Question: Guidance considerations and risk adjustments - Management explained that the guidance reflects a mix of stable growth in core segments and anticipated recovery in diagnostics, with a focus on maintaining high single-digit growth [42][45] Question: Continuous glucose monitor (CGM) growth expectations - Management projected continued strong growth in CGM sales, driven by market expansion opportunities and new product launches [50][56] Question: Capital allocation and M&A strategy - Management indicated a focus on integrating Exact Sciences post-acquisition, with potential for smaller tuck-in acquisitions in the future [69][70]

Financial Performance - Net sales decreased by 15.9% year-over-year to $135.6 million in 1Q25, primarily due to customer channel inventory destocking[5, 17, 20] - Adjusted EBITDA decreased year-over-year to $12.2 million, with an Adjusted EBITDA margin of 9.0%, a 140bps increase compared to 4Q24[8, 10] - Free Cash Flow was $5.4 million in 1Q25, supported by working capital efficiency initiatives[8, 10] - Adjusted Diluted EPS was $0.04 in 1Q25[8, 10] Capital Allocation and Balance Sheet - The company ended 1Q25 with a net leverage of 1.4x, down from 2.0x at the end of 1Q24[8] - $1.7 million of shares were repurchased during the quarter[8] - Total cash and available liquidity stood at $203 million[30] Outlook and Guidance - The company maintained FY25 guidance, supported by strong year-to-date execution and stronger than expected demand within the Military and Other end markets[7] - Revenue for 2025 is projected to be between $560 million and $590 million, representing a decrease of (4%) to 1% year-over-year[32] - Adjusted EBITDA for 2025 is projected to be between $60 million and $66 million, representing a decrease of (7%) to 2% year-over-year[32] - Free cash flow for 2025 is projected to be between $43 million and $50 million, representing a decrease of (45%) to (36%) year-over-year[32] End-Market Outlook - The company anticipates subdued customer demand in the first half of 2025, with gradual improvement in the second half as channel inventory levels normalize[12] - The company expects year-over-year net sales changes in 2025 for the following end markets: Commercial Vehicle: (1%) – (5%), Construction & Access: 0% – (5%), Powersports: (5%) – (15%), Agriculture: (22%) – (28%), Military: 10% – 15%, Other: 18% – 20%[13, 32]